Polymorphs of bicifadine hydrochloride
AssigneeDOV Pharmaceutical, Inc.
InventorsBrenton William Russell, Rex Alwyn Shipplett, Kevin John Halloran
Life of this patent
Estimating the term…
Abstract
A new polymorphic crystalline form of bicifadine hydrochloride, designated form B, which is more thermodynamically stable than the previously known polymorphic form of bicifadine hydrochloride, designated as form A, methods for preparing said crystalline form B and pharmaceutical compositions containing said crystalline form B.
Claims5
A solid composition comprising bicifadine hydrochloride polymorph form B substantially free of bicifadine hydrochloride polymorph form A, said solid composition comprising solid crystals of form B having a distinct infrared profile characterized by one or more of the following infrared spectrum peaks in wavenumbers (cm−1):
- 3185
- 1111
- 2769
- 1022
- 2437
- 963
- 2276
- 904
- 2108
- 891
- 1908
- 856
- 1804
- 818
- 1658
- 783
- 1596
- 719
- 1518
- 684
- 1453
- 660
- 1403
- 637
- 1343
- 580
- 1305
- 532
- 1274
- 475
- 1209
- 422
- 1131
- and a distinct x-ray powder diffraction (XRPD) profile characterized by one or more of the following XRPD peaks expressed in terms of “d” spacings and relative intensities I (s =strong, m=medium, w=weak, v=very, d=diffuse)
- 2θ (deg)
- d (Å)
- Ia
- 5.08
- 17.39
- Vs
- 10.07
- 8.77
- S
- 15.19
- 5.83
- S
- 16.83
- 5.27
- S
- 18.64
- 4.76
- Md
- 18.76
- 4.73
- Md
- 19.64
- 4.52
- W
- 20.16
- 4.40
- M
- 21.96
- 4.05
- M
- 22.37
- 3.97
- S
- 23.16
- 3.84
- W
- 24.00
- 3.70
- W
- 25.27
- 3.52
- D
- 27.33
- 3.26
- Md
- 27.74
- 3.21
- M
- 29.00
- 3.08
- M
- 30.43
- 2.93
- Md
- 31.84
- 2.80
- Wd
- 32.29
- 2.77
- W
- 35.27
- 2.54
- Wd
- 35.64
- 2.52
- W.
- s = strong, m = medium, w = weak, v = very, d = diffuse
Dependencies are inferred from the claim text.